Optimal treatment of obesity-related hypertension - The Hypertension-Obesity-Sibutramine (HOS) Study

被引:65
作者
Scholze, Juergen
Grimm, Elmar
Herrmann, Dana
Unger, Thomas
Kintscher, Ulrich
机构
[1] Charite Univ Med Berlin, CCM, Outpatient Clin, Dept Med, D-10117 Berlin, Germany
[2] Charite Univ Med Berlin, Cardiovasc Res Ctr, CCM, Inst Pharmacol, D-10117 Berlin, Germany
关键词
drugs; glucose; hypertension; obesity; metabolism;
D O I
10.1161/CIRCULATIONAHA.106.625400
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background-Current guidelines for the treatment of hypertension do not provide specific recommendations for obese hypertensive patients. To identify an optimal treatment regimen for obese hypertensive patients, we studied the interactions between a drug-based weight loss approach by sibutramine and different antihypertensive drug regimens. Methods and Results-This was a prospective, 16-week double-blind placebo-controlled randomized multicenter study in 171 obese hypertensive patients. After a 2-week run-in period, patients receiving 1 of the 3 antihypertensive combination therapies ( felodipine 5 mg/ramipril 5 mg [ n=57], verapamil 180 mg/trandolapril 2 mg [ n=55], or metoprolol succinate 95 mg/hydrochlorothiazide 12.5 mg [ metoprolol/hydrochlorothiazide; n=59]) were assigned randomly to sibutramine ( 15 mg) or placebo. Sibutramine treatment resulted in a significantly greater decrease in body weight, body mass index, and waist circumference and a significant increase in diastolic blood pressure during 24-hour blood pressure monitoring compared with placebo treatment. Sibutramine-induced weight loss and reduction of visceral obesity were markedly attenuated in the metoprolol/hydrochlorothiazide group compared with the other groups. Consistently, improvement in glucose tolerance and hypertriglyceridemia by sibutramine was abrogated in the cohort treated with metoprolol/hydrochlorothiazide compared with the other groups. Conclusions-The present study demonstrates for the first time that an antihypertensive combination therapy regimen with angiotensin-converting enzyme inhibitors and calcium channel blockers is more advantageous than a beta-blocker/diuretic-based regimen in supporting the weight-reducing actions and concomitant metabolic changes induced by sibutramine in obese hypertensive patients. These data may help to develop future comprehensive treatment strategies and guidelines for this high-risk patient population.
引用
收藏
页码:1991 / 1998
页数:8
相关论文
共 30 条
  • [1] The metabolic syndrome - a new worldwide definition
    Alberti, KGMM
    Zimmet, P
    Shaw, J
    [J]. LANCET, 2005, 366 (9491) : 1059 - 1062
  • [2] Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension - A randomized controlled trial
    Bakris, GL
    Fonseca, V
    Katholi, RE
    McGill, JB
    Messerli, FH
    Phillips, RA
    Raskin, P
    Wright, JT
    Oakes, R
    Lukas, MA
    Anderson, KM
    Bell, DSH
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2004, 292 (18): : 2227 - 2236
  • [3] Paradoxical effect of sibutramine on autonomic cardiovascular regulation
    Birkenfeld, AL
    Schroeder, C
    Boschmann, M
    Tank, J
    Franke, G
    Luft, FC
    Biaggioni, I
    Sharma, AM
    Jordan, J
    [J]. CIRCULATION, 2002, 106 (19) : 2459 - 2465
  • [4] Sibutramine produces dose-related weight loss
    Bray, GA
    Blackburn, GL
    Ferguson, JM
    Greenway, FL
    Jain, AK
    Mendel, CM
    Mendels, J
    Ryan, DH
    Schwartz, SL
    Scheinbaum, ML
    Seaton, TB
    [J]. OBESITY RESEARCH, 1999, 7 (02): : 189 - 198
  • [5] Sibutramine and blood pressure: a therapeutic dilemma
    Bray, GA
    [J]. JOURNAL OF HUMAN HYPERTENSION, 2002, 16 (01) : 1 - 3
  • [6] DONAHUE RP, 1987, LANCET, V1, P821
  • [7] Prevention conference VII -: Obesity, a Worldwide Epidemic Related to Heart Disease and Stroke -: Executive summary
    Eckel, RH
    York, DA
    Rössner, S
    Hubbard, V
    Caterson, I
    St Jeor, ST
    Hayman, LL
    Mullis, RM
    Blair, SN
    [J]. CIRCULATION, 2004, 110 (18) : 2968 - 2975
  • [8] Secular trends in cardiovascular disease risk factors according to body mass index in US adults
    Gregg, EW
    Cheng, YLJ
    Cadwell, BL
    Imperatore, G
    Williams, DE
    Flegal, KM
    Narayan, KMV
    Williamson, DF
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2005, 293 (15): : 1868 - 1874
  • [9] Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension:: principal results of the hypertension optimal treatment (HOT) randomised trial
    Hansson, L
    Zanchetti, A
    Carruthers, SG
    Dahlöf, B
    Elmfeldt, D
    Julius, S
    Ménard, J
    Rahn, KH
    Wedel, H
    Westerling, S
    [J]. LANCET, 1998, 351 (9118) : 1755 - 1762
  • [10] Obesity
    Haslam, DW
    James, WPT
    [J]. LANCET, 2005, 366 (9492) : 1197 - 1209